专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明授权

US5500443A New benzodioxane compounds 失效
标题翻译：新的苯并二恶烷化合物
公开(公告)号：US5500443A
公开(公告)日：1996-03-19
申请号：US392203
申请日：1995-02-22
申请人： Gilbert Lavielle , Patrick Hautefaye , Olivier Muller , Mark Millan , Mauricette Brocco
发明人： Gilbert Lavielle , Patrick Hautefaye , Olivier Muller , Mark Millan , Mauricette Brocco
IPC分类号： C07D319/16 , A61K31/00 , A61K31/335 , A61K31/357 , A61K31/40 , A61K31/4025 , A61K31/443 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/453 , A61K31/55 , A61P25/18 , A61P25/22 , C07D319/18 , C07D319/20 , C07D405/12 , C07D405/14 , C07D413/14 , C07D207/04
CPC分类号： C07D405/12 , C07D319/18 , C07D319/20 , C07D405/14 , C07D413/14
摘要： A compound of formula (I): ##STR1## in which: X represents oxygen or methylene,n represents 1, 2 or 3,R.sub.1 represents hydrogen, aminocarbonyl or hydroxymethyl,R.sub.2 represents: ##STR2## in which R.sub.3 and R.sub.4 are as defined in the description, the isomers thereof and the addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same are useful in the treatment of schizophrenia.
摘要翻译：式（I）的化合物：其中：X表示氧或亚甲基，n表示1,2或3，R1表示氢，氨基羰基或羟甲基，R2表示：其中R3和R4 如本说明书中所定义，其异构体及其与药学上可接受的酸或碱的加成盐，以及含有它们的药物可用于治疗精神分裂症。

42. 发明授权

US08247441B2 Chromene compounds, a process for their preparation and pharmaceutical compositions containing them 失效
标题翻译：色烯化合物，其制备方法和含有它们的药物组合物
公开(公告)号：US08247441B2
公开(公告)日：2012-08-21
申请号：US12804355
申请日：2010-07-20
申请人： Guillaume De Nanteuil , Bernard Cimetiere , Anne Dekeyne , Mark Millan
发明人： Guillaume De Nanteuil , Bernard Cimetiere , Anne Dekeyne , Mark Millan
IPC分类号： A61K31/407 , C07D209/58
CPC分类号： C07D491/04
摘要： The invention relates to compounds of formula (I): wherein R1 and R2 together form the following carbon-containing chain: wherein: R3 represents a hydrogen atom or an alkyl group, R4 represents a hydrogen atom or an alkyl, aryl, heteroaryl, 3,4-dioxocyclobutenyl, alkylcarbonyl, cycloalkylcarbonyl, heterocycloalkylcarbonyl, benzoyl, arylsulphonyl or heteroarylsulphonyl group, each of those groups optionally being substituted, or R3 and R4 together with the nitrogen atom carrying them form a 5- to 8-membered ring, the ring thereby formed optionally being substituted. Medicinal products containing the same which are useful in treating conditions requiring a D3 receptor antagonist.
摘要翻译：本发明涉及式（I）化合物：其中R 1和R 2一起形成以下含碳链：其中：R 3表示氢原子或烷基，R 4表示氢原子或烷基，芳基，杂芳基，3 ，4-二氧环戊烯基，烷基羰基，环烷基羰基，杂环烷基羰基，苯甲酰基，芳基磺酰基或杂芳基磺酰基，这些基团任选被取代，或者R3和R4与携带它们的氮原子一起形成5-至8-元环，形成任选地被取代。含有该药物的药物可用于治疗需要D3受体拮抗剂的病症。

43. 发明授权

US07960438B2 Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder 有权
标题翻译：在获得旨在治疗广泛性焦虑症的药物中使用阿格美林
公开(公告)号：US07960438B2
公开(公告)日：2011-06-14
申请号：US11732762
申请日：2007-04-04
申请人： Bruno Delalleau , Agnes Fabiano , Mark Millan , Elisabeth Mocaer
发明人： Bruno Delalleau , Agnes Fabiano , Mark Millan , Elisabeth Mocaer
IPC分类号： A61K31/07
CPC分类号： A61K31/04 , A61K31/165
摘要： The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Generalized Anxiety Disorder.
摘要翻译：本发明涉及在获得旨在治疗广泛性焦虑障碍的药物中使用阿德米苷或N- [2-（7-甲氧基-1-萘基）乙基]乙酰胺。

44. 发明授权

US07435850B2 Naphthalene compounds 失效
公开(公告)号：US07435850B2
公开(公告)日：2008-10-14
申请号：US11824392
申请日：2007-06-29
申请人： Said Yous , Basile Peres , Ahmed Sabaouni , Pascal Berthelot , Michael Spedding , Philippe Delagrange , Daniel-Henri Caignard , Mark Millan
发明人： Said Yous , Basile Peres , Ahmed Sabaouni , Pascal Berthelot , Michael Spedding , Philippe Delagrange , Daniel-Henri Caignard , Mark Millan
IPC分类号： C07C233/00 , C07C235/00 , C07C237/00 , C07C239/00
CPC分类号： C07C233/18
摘要： A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.

45. 发明授权

US06350757B1 Beta-carboline compounds 失效
标题翻译： β-咔啉化合物
公开(公告)号：US06350757B1
公开(公告)日：2002-02-26
申请号：US09621742
申请日：2000-07-21
申请人： Solo Goldstein , Guillaume Poissonnet , Jean-Gilles Parmentier , Jean-Daniel Brion , Mark Millan , Anne Dekeyne , Jean Boutin
发明人： Solo Goldstein , Guillaume Poissonnet , Jean-Gilles Parmentier , Jean-Daniel Brion , Mark Millan , Anne Dekeyne , Jean Boutin
IPC分类号： C07D47114
CPC分类号： C07D471/04
摘要： A compound selected from those of formula (I): wherein: represents single or double bond, R1 represents hydrogen, alkyl, —R6-aryl, —R6-cycloalkyl, —R6-heterocycle, —CO2R7—, —COR8, or —CONHR8, wherein R6, R7, and R8 are as defined in the description, R2 represents cyano, mono- or di-alkylaminoalkylaminocarbonyl, —CO2R8, —CONHR8, —NR8R9, —NHCO2R7, or —COR8 wherein R7, R8, and R9 are as defined in the description, R3 and R4 together form (C3-C10)cycloalkyl, R5 represents hydrogen, alkyl, or arylalkyl, Ra, Rb, Rc, Rd, which may be identical or different, represent a group as defined in the description, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same which are useful in the treatment of CNS disorders.
摘要翻译：选自式（I）的化合物：其中：CUSTOM-CHARACTER FILE =“US06350757-20020226-P00900.TIF”ID =“CUSTOM-CHARACTER-00001”>表示单键或双键，R1表示氢，烷基， -R6-芳基，-R6-环烷基，-R6-杂环，-CO2R7-，-COR8或-CONHR8，其中R6，R7和R8如说明书中所定义，R 2表示氰基，单或二烷基氨基烷基氨基羰基，-CO 2 R 8，-CONHR 8，-NR 8 R 9，-NHCO 2 R 7或-COR 8，其中R 7，R 8和R 9如说明书中所定义，R 3和R 4一起形成（C 3 -C 10）环烷基，R 5表示氢，烷基或芳烷基可以相同或不同的R a，R b，R c，R d表示本说明书中定义的基团，其异构体及其药学上可接受的酸或碱加成盐，以及含有该基团的药物，其可用于治疗中枢神经系统疾病。

46. 发明授权

US6127396A Imidazoline compounds 失效
标题翻译：咪唑啉化合物
公开(公告)号：US6127396A
公开(公告)日：2000-10-03
申请号：US466716
申请日：1999-12-17
申请人： Alex Cordi , Jean-Michel Lacoste , Mark Millan , Adrian Newman-Tancredi , Alain Gobert
发明人： Alex Cordi , Jean-Michel Lacoste , Mark Millan , Adrian Newman-Tancredi , Alain Gobert
IPC分类号： C07D233/06 , A61K31/4164 , A61P3/04 , A61P15/10 , A61P25/00 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P43/00 , C07D233/10 , C07D233/20 , C07D233/22 , C07D401/06 , C07D405/06 , A61K31/415 , C07D233/02 , C07D233/08
CPC分类号： C07D405/06 , C07D233/10 , C07D233/20 , C07D233/22 , Y02P20/55
摘要： The invention relates to a compound of formula (I): ##STR1## wherein: A represents an optionally substituted benzene ring,B represents an imidazoline ring of formula (Ia) or (Ib): ##STR2## X represents CR.sup.6, CR.sup.6 R.sup.7, NR.sup.8, SO or SO.sub.2, or oxygen, nitrogen or sulphur,Y represents a single bond or CH or CH.sub.2,Z represents a carbon atom or CR.sup.4,R.sup.1, R.sup.2, R.sup.3, which may be the same or different, each represent hydrogen or alkyl, it being possible for (R.sup.1 and R.sup.4) or (R.sup.2 and R.sup.4) to form cyclopropane,R.sup.5 represents hydrogen, alkyl or benzyl.
摘要翻译：本发明涉及式（I）化合物：其中：A表示任选取代的苯环，B表示式（Ia）或（Ib）的咪唑啉环：X表示CR6，CR6R7，NR8，SO或SO2，或氧，氮或硫，Y表示单键或CH或CH 2，Z表示碳原子或CR 4，可以相同或不同的R 1，R 2，R 3各自表示氢或烷基，可以（R 1 和R 4）或（R 2和R 4）以形成环丙烷，R 5表示氢，烷基或苄基。

47. 发明申请

US20120309838A1 USE OF AGOMELATINE IN OBTAINING MEDICAMENTS INTENDED FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD) 审中-公开
标题翻译：用于治疗感染性恶心症（OCD）的药物治疗药物的使用
公开(公告)号：US20120309838A1
公开(公告)日：2012-12-06
申请号：US13578383
申请日：2011-02-10
申请人： Laurence Laigle , Elisabeth Mocaer , Mark Millan
发明人： Laurence Laigle , Elisabeth Mocaer , Mark Millan
IPC分类号： A61K31/165 , A61P25/00
CPC分类号： A61K31/165
摘要： The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Obsessive-Compulsive Disorder (OCD).
摘要翻译：本发明涉及在获得用于治疗强迫症（OCD）的药物中使用阿米苏定或N- [2-（7-甲氧基-1-萘基）乙基]乙酰胺。

48. 发明申请

US20110021490A1 Chromene compounds, a process for their preparationand pharmaceutical compositions containing them 失效
标题翻译：色烯化合物，其制备方法和含有它们的药物组合物
公开(公告)号：US20110021490A1
公开(公告)日：2011-01-27
申请号：US12804355
申请日：2010-07-20
申请人： Guillaume De Nanteuil , Bernard Cimetiere , Anne Dekeyne , Mark Millan
发明人： Guillaume De Nanteuil , Bernard Cimetiere , Anne Dekeyne , Mark Millan
IPC分类号： A61K31/397 , C07D491/052 , A61K31/407 , C07D401/06 , A61K31/4439 , C07D405/14 , A61K31/506 , A61P25/00
CPC分类号： C07D491/04
摘要： The invention relates to compounds of formula (I): wherein R1 and R2 together form the following carbon-containing chain: wherein: R3 represents a hydrogen atom or an alkyl group, R4 represents a hydrogen atom or an alkyl, aryl, heteroaryl, 3,4-dioxocyclobutenyl, alkylcarbonyl, cycloalkylcarbonyl, heterocycloalkylcarbonyl, benzoyl, arylsulphonyl or heteroarylsulphonyl group, each of those groups optionally being substituted, or R3 and R4 together with the nitrogen atom carrying them form a 5- to 8-membered ring, the ring thereby formed optionally being substituted. Medicinal products containing the same which are useful in treating conditions requiring a D3 receptor antagonist.
摘要翻译：本发明涉及式（I）化合物：其中R 1和R 2一起形成以下含碳链：其中：R 3表示氢原子或烷基，R 4表示氢原子或烷基，芳基，杂芳基，3 ，4-二氧环戊烯基，烷基羰基，环烷基羰基，杂环烷基羰基，苯甲酰基，芳基磺酰基或杂芳基磺酰基，这些基团任选被取代，或者R3和R4与携带它们的氮原子一起形成5-至8-元环，形成任选地被取代。含有该药物的药物可用于治疗需要D3受体拮抗剂的病症。

49. 发明申请

US20080004349A1 Naphthalene compounds 失效
公开(公告)号：US20080004349A1
公开(公告)日：2008-01-03
申请号：US11823771
申请日：2007-06-28
申请人： Said Yous , Basile Peres , Ahmed Sabaouni , Pascal Berthelot , Michael Spedding , Philippe Delagrange , Daniel-Henri Caignard , Mark Millan
发明人： Said Yous , Basile Peres , Ahmed Sabaouni , Pascal Berthelot , Michael Spedding , Philippe Delagrange , Daniel-Henri Caignard , Mark Millan
IPC分类号： A61K31/165 , A61P25/00 , C07C233/17
CPC分类号： C07C233/18
摘要： A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.

50. 发明申请

US20050059675A1 Benzoindoline compounds 失效
标题翻译：苯并二氢吲哚化合物
公开(公告)号：US20050059675A1
公开(公告)日：2005-03-17
申请号：US10925712
申请日：2004-08-25
申请人： Gilbert Lavielle , Olivier Muller , Mark Millan , Alain Gobert , Benjamin Di Cara
发明人： Gilbert Lavielle , Olivier Muller , Mark Millan , Alain Gobert , Benjamin Di Cara
IPC分类号： A61K31/496 , A61P15/00 , A61P15/10 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D209/60 , C07D401/12 , C07D403/12 , C07D43/02
CPC分类号： C07D209/60
摘要： A compound of formula (I): wherein: R1 and R2 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, and R3 and R4 represent hydrogen, or R1 and R4 represent hydrogen and R2 and R3 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, or R1 and R2 represent hydrogen and R3 and R4 together form a benzo ring optionally substituted by halogen or by alkyl, alkoxy, cyano, nitro, hydroxy, amino, alkylamino, dialkylamino or trifluoromethyl, addition salts thereof with a pharmaceutically acceptable acid or base, and methods of treating conditions susceptible to α2-AR/5-HT2C antagonists.
摘要翻译：式（I）化合物：其中：R 1和R 2一起形成任选被卤素取代的苯并环，或烷基，烷氧基，氰基，硝基，羟基，氨基，烷基氨基，二烷基氨基或三氟甲基，R R 3和R 4代表氢，或R 1和R 4代表氢，R 2和R 3一起形成任选地被卤素取代的苯并环，或烷基，烷氧基，氰基，硝基，羟基，氨基，烷基氨基，二烷基氨基或三氟甲基，或R 1和R 2表示氢，R 3和R 4一起形成任选被卤素取代的苯并环，或烷基，烷氧基，氰基，硝基，羟基，氨基，烷基氨基，二烷基氨基或三氟甲基，其与药学上可接受的酸或碱的加成盐，以及治疗对α2-AR / 5-HT2C拮抗剂敏感的病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式